At the end of November, the ARPharM adopted the ARPharM Code for Disclosure of Transfers of Value by Pharmaceutical Companies to Healthcare Professionals and Health Organizations. In doing so, the ARPharM adopted the standards established by the European umbrella association for the research-based pharmaceutical industry (EFPIA, www.efpia.eu) in the EFPIA Transparency Code (adoption: end of June 2013) in its national code for Bulgaria.
According to the new Disclosure Code, all future payments in kind by the pharmaceutical industry to physicians and further healthcare professionals, along with organisations in the healthcare sector, must be made public.
As a supplement to the established standards of conduct in the ARPharM Code of Ethics of the research-based pharmaceutical industry in Bulgaria for the interactions with Healthcare Professionals and the ARPharM Code of Practice on Relationships between the Research-based Pharmaceutical Industry and Patient Organizations in Bulgaria, the new code will place collaborative exchange on an even more solid footing.
This development is an important step towards more transparency and the strengthening of trust of the public at large in the collaboration between companies and healthcare professionals.
The Key Provisions of the Disclosure Code
The Disclosure Code will apply to all member companies of the ARPharM, as well as to their domestic subsidiaries. The documentation shall include all direct and indirect payments in kind and benefits in kind from the following areas:
On the basis of two hypothetical examples, we would like to briefly illustrate what disclosure according to the Disclosure Code might look like in the future.
Dr. Ivanov Sample, Sampleman Street 1 in 12345 Sampletown, Unified Identification Number (UIN), received benefits in kind in the amount of 1,500 Euros from Company ABC Pharma in the period from 01 January 2015 to 30 June 2015 in the scope of contractual collaboration.
In July 2015, the Example Clinic, Example Street 4 in 56789 Exampletown, received a financial payment in the amount of 5,000 Euros from Pharma XYZ for scientific consultation on the topic Z.
Over 66% of the healthcare professionals in Bulgaria have consented to disclosing their cooperation with pharmaceutical companies within the initiative “Transparency Builds Trust”
In June 2017 for a second consecutive year the pharmaceutical industry in Europe disclosed the…[read more]
Over 60% of the healthcare professionals in Bulgaria have consented to disclosing their cooperation with pharmaceutical companies within the initiative “Transparency builds trust”
On 28.06.2016 the Association of Research-Based Pharmaceutical Companies in Bulgaria (ARPharM) held…[read more]
ARPharM adopted the Code for Disclosure of Transfers of Value by Pharmaceutical Companies to Healthcare Professionals and Health Organizations
On November 26, 2013 the Association of Research- based Pharmaceutical Manufacturers in Bulgaria (ARPharM)…[read more]
Disclaimer of liability
Certain links in this website will lead to websites that are not under the control of ARPharM. When you activate these you will leave the ARPharM website. ARPharM has no control over and accepts no liability in respect of materials, data, products or services available on any website which is not under the control of ARPharM. [read more]
- Code for Disclosure of Transfers of Value by Pharmaceutical Companies to Healthcare Professionals and Health Organizations
- EFPIA Code - Introducing the EFPIA Disclosure Code
- EFPIA Code - Answering Your Questions
- EFPIA Code - 10 Facts for Healthcare Practitioners
- EFPIA Code - 10 Key Messages
- EFPIA Code - Responsible Transparency